Michael Mollerus

Davis Polk advised AC Immune SA in connection with its $117.5 million U.S. follow-on public offering. AC Immune sold 8,500,000 of its newly issued common shares and subscription rights…

Davis Polk is advising MSCI on its sale of InvestorForce to Resurgens Technology Partners. The transaction is expected to close within the next three months and is subject to customary…

Davis Polk advised IHS Markit Ltd. in connection with its SEC-registered offering of $1.25 billion aggregate principal amount of senior notes in two series, consisting of $500 million…

Davis Polk is advising Aptiv PLC on its acquisition of Winchester Interconnect from an affiliate of Snow Phipps Group for $650 million. The transaction is subject to regulatory approval and…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $100 million initial public offering of common stock of Magenta…

Davis Polk advised the sole book-running manager in connection with an SEC-registered common stock offering of 12,000,000 shares of common stock of Tellurian Inc. The net proceeds from…

Davis Polk is advising Roche on its acquisition of the outstanding shares of Foundation Medicine, Inc. not already owned by Roche at a price of $137.00 per share in cash. The transaction is…

Davis Polk advised the joint book-running managers in connection with the $172 million public offering of common stock of Deciphera Pharmaceuticals, Inc. The common stock is listed on…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Kennametal Inc. of $300 million aggregate principal amount of 4.625% senior notes due 2028. …

Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to which its indirect wholly owned subsidiary, Valeant Pharmaceuticals…